United Parks & Resorts (PRKS), owner of theme parks like SeaWorld, faces declining attendance and revenue due to price hikes and economic weakness. Management aims to save $90–$100 million over two years through AI, automation, and real estate sales to boost profitability. Despite challenges, PRKS trades at low multiples with better leverage than peers, supporting a buy rating. Recovery in attendance could significantly increase EBITDA and justify a premium valuation.
United Parks & Resorts faces short-term challenges with declining attendance and revenue. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 12, 2026 22:11 WIB: Of 134 priced US stocks, 43 rose and 89 fell. Notable movers include Quantumscape Corp (QS) at USD 3.95 with a 1-day change of -6.18% and 89% sell order activity, Stellantis N.V. (STLA) at USD 3.92 down 4.62%, and Victoria's Secret & Co (VSXY) at USD 105.01 down 4.41% but with 93% buy order activity and a typical hold time of 35 days on Pluang.
D.A. Davidson raised Riskified's price target to $12, reflecting a 22.2% potential upside from $9.82. The company reported a 41% revenue increase to $115.2 million and adjusted earnings of $0.07 per share, beating estimates. Profitability improved wi...
TRM Labs introduced the Disruption Awards to recognize coalitions of public and private organizations that successfully disrupted major cybercrimes in 2026. Winners include groups that took down a phishing service responsible for most Microsoft-block...
Existing-home sales in the U.S. dropped 5.5% month-over-month and 8.8% year-over-year in October, reaching the lowest level since August 2010. The decline is attributed to mortgage rates rising to their highest since 2000, making home buying more dif...
The global specialty zeolites market, valued at $1 million in 2025, is projected to reach $1.5 million by 2032 with a 5.8% CAGR. Growth is fueled by stricter environmental regulations and rising demand in water treatment, petrochemicals, agriculture,...
The global cell lysis and cell fractionation market, valued at $2.8 billion in 2025, is projected to grow to $4.5 billion by 2032 at a 7% CAGR. Growth is fueled by advances in biotechnology, increased life sciences research investments, and rising de...
